knowledge -WSS

knowledge

author：hotspot 2025-09-06 04:34:04 - browse：193

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： How are insurers handling Leqembi and related scans?

WSS

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Superbugs, antibiotic resistance get scrutiny in congress

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Superbugs, antibiotic resistance get scrutiny in congress

EU fines Illumina $475 million over Grail acquisition

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Wikipedia

knowledge

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Companies helping big Covid

Tori Bowie and the unacceptable rates of Black maternal death

Watch the official trailer for 'Ahsoka' series

Medicare proposal to cover medical devices draws a mixed reaction

Opioid cravings were reduced by anti

Sports medicine is finally prioritizing gender equality

Reporting on presidential health from Reagan to Trump and Biden

Trump demands the U.S. pay no more for drugs than other countries … again

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

focus

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Antibody drugs appear effective. Now can we make enough of them?

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Ukraine seeks to reclaim its role as a hub for clinical trials

WATCH: Why do our ears pop?

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

entertainment

focus

hotspot

focus